Dare Bioscience, Inc. annual report, FY2017

Business context and reporting period

Daré Bioscience, Inc. (formerly Cerulean Pharma Inc.) filed this Form 10-K for the fiscal year ended December 31, 2017. The company is a clinical-stage biopharmaceutical business focused on women’s reproductive health and had no marketed products or revenue. In July 2017, it completed a business combination with privately held Daré Bioscience Operations, Inc., sold Cerulean’s Dynamic Tumor Targeting platform to Novartis for $6.0 million, changed its name, and refocused on women’s health. The 2017 financial statements reflect operations after the transaction; 2016 reflects the former private Daré business, so period comparisons are limited.

Financial and operating highlights

Metric20172016
Revenue$0$0
Research and development expense$984,749$72,666
General and administrative expense$2,704,853$157,925
Goodwill impairment$7,490,886$0
Net loss$11,503,117$672,687
Comprehensive loss$11,521,197$672,687
Net cash used in operations$2,540,128$372,299

The company reported a basic and diluted loss per share of $3.56 in 2017, versus $0.81 in 2016; the share counts and business scope differ materially between periods. The 2017 goodwill impairment was non-cash and reduced goodwill from $12.68 million to $5.19 million. Increased G&A included transaction costs and newly incurred public-company, personnel, and insurance expenses. R&D growth was primarily related to Ovaprene.

At December 31, 2017, cash and cash equivalents were $7.56 million, working capital was $7.38 million, total assets were $14.26 million, total liabilities were $0.97 million, and stockholders’ equity was $13.29 million. The company had no convertible notes outstanding at year-end; the notes had converted into equity in connection with the 2017 transaction. Operating cash outflow was partly offset in reported cash movement by $9.92 million of cash acquired in the business combination; financing activities provided $155,000.

After year-end, the company received approximately $1.04 million net from ATM sales and approximately $9.4 million net from a February 2018 public offering. Management stated that cash, including these proceeds, was expected to fund operations for at least 12 months and support an Ovaprene postcoital trial and advancement of SST-6007 into Phase 2b. The filing estimates net cash needed for 2018 operating expenses at approximately $11 million, excluding potentially material added costs from new products or candidates.

Material changes and business developments

  • Ovaprene, a non-hormonal monthly contraceptive vaginal ring, was licensed from ADVA-Tec in 2017. The FDA had designated it a device-primary combination product requiring a Premarket Approval (PMA).
  • In February 2018, Daré obtained an exclusive worldwide license for SST-6007, topical sildenafil cream for female sexual arousal disorder (FSAD). The company planned to pursue a 505(b)(2) pathway and expected a Phase 2b trial in the second half of 2018, subject to FDA authorization.
  • Management expected an Ovaprene postcoital clinical trial to begin in the first half of 2018; successful results would be required before a Phase 3 pivotal trial could commence.
  • The February 2018 offering issued 5.0 million common shares and warrants for up to 3.5 million shares, with an additional underwriter warrant allotment disclosed. The warrants have price-based anti-dilution provisions. As of March 26, 2018, 11,422,161 common shares were outstanding.

Outlook, risks, contingencies, and unusual items

The company expects continued operating losses and negative operating cash flows for at least several years and says additional capital will be needed to advance its candidates, pursue pivotal studies, and potentially add pipeline assets. There is no assurance that financing will be available on acceptable terms. Failure to raise capital could force delays, reductions, or termination of development programs.

Key risks include clinical or regulatory failure or delay; uncertainty over Ovaprene’s safety, contraceptive efficacy, and FDA requirements; uncertainty in trial design and patient selection for SST-6007; competition, reimbursement, and market acceptance; dependence on licensors, CROs, and third-party manufacturers (including single-source Ovaprene components); and limited staff and no internal sales or marketing infrastructure.

License obligations are material and contingent on development and commercial outcomes. Ovaprene includes up to $14.6 million in development and regulatory milestones, up to $20 million in commercial milestones, and tiered royalties of 1%–10%. SST-6007 includes milestone payments ranging from $500,000 to $150 million, tiered royalties from single digits to the mid-double digits, and a share of sublicense revenue. Timing and likelihood of these payments are uncertain. No material pending legal proceedings were reported.

The 2017 goodwill impairment was a significant non-cash charge. The company also disclosed that its deferred tax assets were fully offset by a valuation allowance; utilization of tax-loss and credit carryforwards may be limited, including by ownership-change rules. Management reported disclosure controls and internal control over financial reporting as effective at December 31, 2017; the auditor did not provide an internal-control attestation.

Important facts for investors to verify

  • Whether financing and cash use support the stated runway, given the approximately $11 million estimated 2018 operating cash need and ongoing development obligations.
  • Progress, timing, trial design, safety, and efficacy results for the planned Ovaprene postcoital study and SST-6007 Phase 2b trial, and any changes in FDA requirements.
  • Potential dilution and financing constraints associated with the February 2018 warrants, their anti-dilution terms, ATM capacity, and subsequent share issuances.
  • The terms, development responsibilities, and potential milestone, royalty, and termination consequences of the ADVA-Tec and Strategic Science licenses.
  • The effect of the 2017 business combination and goodwill impairment on comparability, and the final valuation and tax treatment of acquired assets and tax attributes.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.